コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 Clofazimine is a weakly basic, Food and Drug Administration-approved antibiotic recommended by the World Health Organizat
2 urposing screening to identify Food and Drug Administration-approved chemotherapeutic compounds possessing synergistic ac
3 hase II to IV cancer trials of Food and Drug Administration-approved immunotherapy drugs and selected those reporting res
4 a metabolic pathway that can be targeted by new and already approved drugs to treat fragile X patients.
5 geting the vasculature, GSCs, and GECs, using drugs already approved by the FDA, can reduce both tumor size and invasiven
6 d antiviral activity in the nonhuman primate models already approved for another indication or for which there was existi
8 A number of injectable hydrogels are approved by FDA as surgery sealants, tissue adhesives, and ar
9 e scope of the outbreak combined with the lack of available approved treatment options, there was strong motivation to in
12 Materials and Methods For this institutional review board-approved HIPAA-compliant retrospective study, adult patients
13 Methods In this HIPAA-compliant, institutional review board-approved retrospective cohort study, an institutional databas
14 d Methods In this retrospective, institutional review board-approved study, 41 pediatric patients (age range, 3-17 years)
15 ultireader, multi-institutional, institutional review board-approved, HIPAA-compliant retrospective analysis of 92 patien
16 Sorafenib is the only chemotherapeutic approved for treatment of advanced hepatocellular carcinoma (
20 sing a library of 106 US Food and Drug Administration (FDA)-approved anticancer drugs or compounds currently in clinical
21 ative breast cancers (TNBC) are highly aggressive, lack FDA-approved targeted therapies, and frequently recur, making the
23 itroSynapsin, a new dual-action compound related to the FDA-approved drug memantine, representing an uncompetitive/fast o
24 -modified peptide (RK-10-Biotin) was tested against the FDA-approved SP263 clone on biopsied patient tissues.
25 -tositumomab and (90)yttrium-ibritumomab tiuxetan, were FDA-approved more than a decade ago but have been little utilized
26 ted a comprehensive evaluation of 304 inhibitors, including approved and investigational agents, comparing ex vivo respon
27 tions and indications for active pharmaceutical ingredients approved by FDA and other regulatory agencies.
28 Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes.
31 The B2 receptor antagonist icatibant is approved for treatment of attacks of hereditary angioedema.
32 Vismodegib, a first-in-class Hedgehog-pathway inhibitor, is approved for use in adults with advanced basal-cell carcinoma
34 This review will focus on the current CE-mark approved bioresorbable scaffolds, their basic characteristics
35 However, beyond BRCA1/2 mutations, there are no approved biomarkers for olaparib in high-grade serous ovarian
37 m the market; danaparoid access has been limited and is not approved in the United States; and argatroban is contraindica
42 Left atrial appendage closure (LAAC) was approved by the U.S. Food and Drug Administration (FDA) as a
43 rgeted oligonucleotide-based drug (nusinersen/Spinraza) was approved by US Food and Drug Administration (FDA) in late 201
44 als and Methods This single-center, retrospective study was approved by the institutional review board and compliant with
47 ls and Methods This HIPAA-compliant retrospective study was approved by the institutional review board; the requirement t
48 Materials and Methods This case-control study was approved by the local research ethics committee.
49 ts from a prospective cohort study were included, which was approved by the local ethics board and written informed conse
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。